Needham Reiterates Buy on Collegium Pharmaceutical, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Collegium Pharmaceutical (NASDAQ:COLL) and maintained a $35 price target.
May 30, 2023 | 10:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger reiterated a Buy rating on Collegium Pharmaceutical (NASDAQ:COLL) and maintained a $35 price target.
The reiteration of a Buy rating and maintaining a $35 price target by Needham analyst Serge Belanger indicates a positive outlook for Collegium Pharmaceutical. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100